Revenue growth has turned negative at -3.2% in 2026Q1, while gross margins have compressed to 36.5% from mid-2025 levels of approximately 40%.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 |
|---|
| Sales/Revenue | 7.45B | 7.23B | 7.21B | 6.59B | 6.06B | 4.93B | 5.34B | 5.1B | 4.49B | 4.32B | 4.05B | 3.93B | 3.36B | 2.74B | 2.62B | 1.8B | 990.73M | 913.19M | 814.31M | 703.29M | 648.8M | 524.28M |
| Revenue Growth % | 1.02% | 0.2% | 9.41% | 8.71% | 22.92% | -7.62% | 4.73% | 13.64% | 3.91% | 6.62% | 2.93% | 17.26% | 22.38% | 4.61% | 45.96% | 81.24% | 8.49% | 12.14% | 15.79% | 8.4% | 23.75% | - |
| Cost of Goods Sold | 4.64B | 4.65B | 4.42B | 4.11B | 3.85B | 2.97B | 3.08B | 2.76B | 2.44B | 2.17B | 2.14B | 2B | 1.66B | 1.32B | 1.29B | 466.7M | 227.6M | 172.04M | 175.68M | 179.43M | 203.17M | 153.9M |
| COGS % of Revenue | - | 64.3% | 61.25% | 62.33% | 63.49% | 60.22% | 57.77% | 54.08% | 54.32% | 50.16% | 52.78% | 50.92% | 49.36% | 48.29% | 49.27% | 25.99% | 22.97% | 18.84% | 21.57% | 25.51% | 31.32% | 29.35% |
| Gross Profit | 2.81B | 2.58B | 2.79B | 2.48B | 2.21B | 1.96B | 2.26B | 2.34B | 2.05B | 2.15B | 1.91B | 1.93B | 1.7B | 1.42B | 1.33B | 1.33B | 763.13M | 741.15M | 638.63M | 523.87M | 445.63M | 370.38M |
| Gross Margin % | 37.68% | 35.7% | 38.75% | 37.67% | 36.51% | 39.78% | 42.23% | 45.92% | 45.68% | 49.84% | 47.22% | 49.08% | 50.64% | 51.71% | 50.73% | 74.01% | 77.03% | 81.16% | 78.43% | 74.49% | 68.68% | 70.65% |
| Gross Profit Growth % | - | -7.68% | 12.53% | 12.19% | 12.8% | -12.97% | -3.68% | 14.23% | -4.76% | 12.54% | -0.97% | 13.64% | 19.84% | 6.64% | 0.05% | 74.14% | 2.97% | 16.05% | 21.91% | 17.56% | 20.32% | - |
| Operating Expenses | 1.55B | 1.39B | 1.6B | 1.7B | 1.43B | 1.37B | 1.26B | 1.21B | 1.06B | 1.15B | 972.88M | 960.63M | 841.52M | 681.73M | 669.51M | 1.05B | 555M | 516.1M | 410.19M | 351.43M | 359.45M | 306.65M |
| OpEx % of Revenue | - | 19.27% | 22.22% | 25.81% | 23.6% | 27.72% | 23.58% | 23.73% | 23.52% | 26.6% | 24.02% | 24.42% | 25.08% | 24.87% | 25.54% | 58.6% | 56.02% | 56.52% | 50.37% | 49.97% | 55.4% | 58.49% |
| Selling, General & Admin | 1.11B | 1.02B | 1.14B | 1.27B | 1.11B | 1.06B | 985.62M | 942.82M | 814.77M | 860.35M | 775.27M | 736.43M | 660.77M | 558.46M | 545.07M | 917.9M | 472.09M | 441.18M | 350.2M | 300.04M | 313.16M | 265.04M |
| SG&A % of Revenue | - | 14.13% | 15.86% | 19.2% | 18.27% | 21.52% | 18.46% | 18.49% | 18.16% | 19.92% | 19.14% | 18.72% | 19.69% | 20.37% | 20.8% | 51.12% | 47.65% | 48.31% | 43.01% | 42.66% | 48.27% | 50.55% |
| Research & Development | 420.15M | 358.28M | 384.04M | 395.28M | 361.14M | 354.88M | 294.22M | 276.02M | 240.66M | 288.32M | 197.62M | 224.19M | 180.75M | 123.27M | 124.44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 4.96% | 5.32% | 6% | 5.96% | 7.19% | 5.51% | 5.41% | 5.36% | 6.68% | 4.88% | 5.7% | 5.39% | 4.5% | 4.75% | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 13.45M | 74.48M | 40.36M | -37.66M | -48.86M | -20.8M | -8.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 134.24M | 82.91M | 74.92M | 59.99M | 51.4M | 46.29M | 41.61M |
| Operating Income | 1.26B | 1.19B | 1.19B | 782.32M | 782.44M | 595.06M | 996.13M | 1.13B | 994.12M | 1B | 939.41M | 970.37M | 857.69M | 736.12M | 660.08M | 278.86M | 209.68M | 226.53M | 202.96M | 146.35M | 100.49M | 73.59M |
| Operating Margin % | 16.88% | 16.43% | 16.53% | 11.87% | 12.9% | 12.06% | 18.65% | 22.19% | 22.16% | 23.24% | 23.2% | 24.66% | 25.56% | 26.85% | 25.19% | 15.53% | 21.16% | 24.81% | 24.92% | 20.81% | 15.49% | 14.04% |
| Operating Income Growth % | - | -0.4% | 52.37% | -0.02% | 31.49% | -40.26% | -11.95% | 13.81% | -0.92% | 6.81% | -3.19% | 13.14% | 16.51% | 11.52% | 136.71% | 32.99% | -7.44% | 11.61% | 38.68% | 45.64% | 36.56% | - |
| EBITDA | 1.61B | 1.62B | 1.63B | 1.23B | 1.19B | 954.83M | 1.32B | 1.43B | 1.22B | 1.22B | 1.14B | 1.16B | 1.05B | 864.59M | 789.21M | 369.5M | 255.46M | 266.08M | 236.22M | 177.88M | 129.85M | 100.48M |
| EBITDA Margin % | 21.6% | 22.41% | 22.6% | 18.64% | 19.68% | 19.36% | 24.68% | 28.12% | 27.25% | 28.23% | 28.18% | 29.49% | 31.21% | 31.53% | 30.11% | 20.58% | 25.78% | 29.14% | 29.01% | 25.29% | 20.01% | 19.17% |
| EBITDA Growth % | -0.4% | -0.64% | 32.65% | 2.96% | 24.99% | -27.54% | -8.1% | 17.26% | 0.32% | 6.8% | -1.62% | 10.79% | 21.12% | 9.55% | 113.59% | 44.64% | -3.99% | 12.64% | 32.79% | 36.99% | 29.22% | - |
| D&A (Non-Cash Add-back) | 351.03M | 432.24M | 437.9M | 446.42M | 410.98M | 359.77M | 321.53M | 302.45M | 228.61M | 215.49M | 201.87M | 189.75M | 189.47M | 128.47M | 129.13M | 90.64M | 45.78M | 39.55M | 33.26M | 31.53M | 29.36M | 26.9M |
| EBIT | 1.21B | 1.19B | 1.05B | 723.08M | 782.56M | 584.27M | 1.1B | 1.14B | 1B | 945.25M | 941.56M | 914.86M | 792.9M | 712.89M | 647.14M | 250.79M | 187.88M | 216.39M | 184.94M | 133.11M | 71.58M | 49.1M |
| Net Interest Income | -587.72M | -567.67M | -725.1M | -453.63M | -410.68M | -222.26M | -275.44M | -228.77M | -279.28M | -253.67M | -234.9M | -234.49M | -221.97M | -235.12M | -282.44M | -194.8M | -45.13M | -20.02M | -30.72M | -22.79M | -35.99M | -34.31M |
| Interest Income | 9.55M | 32.66M | 48.05M | 62.43M | 33.86M | 11.55M | 9.14M | 114.2M | 13.99M | 9.68M | 9.93M | 5.84M | 3.07M | 4.87M | 1.68M | 5.76M | 2.88M | 6.51M | 2.21M | 2.85M | 4.67M | 3.42M |
| Interest Expense | 597.28M | 600.33M | 773.15M | 516.06M | 444.54M | 233.81M | 284.58M | 324.38M | 274.16M | 249.53M | 228.8M | 224.61M | 209.49M | 215.35M | 284.12M | 200.56M | 33.39M | 12.39M | 12.67M | 9.52M | 8.08M | 8.28M |
| Other Income/Expense | -644.91M | -596.49M | -748.02M | -575.3M | -444.42M | -244.61M | -117.5M | -314.26M | -268.28M | -307.62M | -226.66M | -280.12M | -268.01M | -238.58M | -272.14M | -198.84M | -51.9M | -22.53M | -30.69M | -22.77M | -36.98M | -32.77M |
| Pretax Income | 612.54M | 590.73M | 444M | 207.02M | 338.01M | 350.45M | 878.63M | 817.1M | 725.84M | 695.72M | 712.75M | 690.25M | 589.68M | 497.54M | 387.95M | 80.02M | 157.78M | 203.99M | 172.27M | 123.59M | 63.51M | 40.82M |
| Pretax Margin % | 8.22% | 8.17% | 6.16% | 3.14% | 5.57% | 7.1% | 16.45% | 16.03% | 16.18% | 16.11% | 17.6% | 17.54% | 17.57% | 18.15% | 14.8% | 4.46% | 15.93% | 22.34% | 21.16% | 17.57% | 9.79% | 7.79% |
| Income Tax | 116.69M | 110.46M | 231.19M | 43.35M | 90.11M | 85.13M | 169.64M | 168.46M | 131.44M | 34.41M | 168.21M | 158.81M | 122.6M | 155.48M | 132.57M | 29.8M | 42.52M | 56.42M | 50.15M | 35.24M | 17.82M | 15.31M |
| Effective Tax Rate % | 19.05% | 18.7% | 52.07% | 20.94% | 26.66% | 24.29% | 19.31% | 20.62% | 18.11% | 4.95% | 23.6% | 23.01% | 20.79% | 31.25% | 34.17% | 37.23% | 26.95% | 27.66% | 29.11% | 28.51% | 28.07% | 37.52% |
| Net Income | 415.56M | 386.13M | 156.92M | 42.32M | 185.03M | 188.73M | 618.55M | 625.15M | 596.64M | 662.7M | 545.46M | 532.14M | 470.25M | 345.55M | 256.69M | 50.31M | 115.51M | 147.97M | 121.73M | 87.77M | 45.39M | 25.56M |
| Net Margin % | 5.58% | 5.34% | 2.18% | 0.64% | 3.05% | 3.83% | 11.58% | 12.26% | 13.3% | 15.35% | 13.47% | 13.52% | 14.01% | 12.6% | 9.79% | 2.8% | 11.66% | 16.2% | 14.95% | 12.48% | 7% | 4.87% |
| Net Income Growth % | 112.86% | 146.07% | 270.81% | -77.13% | -1.96% | -69.49% | -1.06% | 4.78% | -9.97% | 21.49% | 2.5% | 13.16% | 36.09% | 34.62% | 410.24% | -56.45% | -21.94% | 21.56% | 38.68% | 93.36% | 77.63% | - |
| Net Income (Continuing) | 495.85M | 480.27M | 212.81M | 163.67M | 247.9M | 265.33M | 708.99M | 648.64M | 594.41M | 661.31M | 544.54M | 531.44M | 467.08M | 342.05M | 255.38M | 50.23M | 115.27M | 147.57M | 122.12M | 88.35M | 45.69M | 25.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 2.39B | 2.33B | 2.72B | 2.15B | 2.33B | 1.79B | 1.61B | 2.27B | 471.05M | 4.89M | 6.5M | 5.19M | 4.76M | 5.94M | 3.97M | 2.49M | 14.35M | 12.16M | 1.25M | 981K | 408K | 121K |
| EPS (Diluted) | 0.61 | 0.57 | 0.23 | 0.09 | 0.31 | 0.27 | 0.73 | 0.94 | 0.87 | 0.97 | 0.80 | 0.78 | 0.69 | 0.51 | 0.38 | 0.08 | 0.26 | 0.31 | 0.25 | 0.18 | 0.11 | 0.06 |
| EPS Growth % | 114.86% | 147.83% | 155.56% | -70.97% | 14.81% | -63.01% | -22.34% | 8.05% | -10.31% | 21.25% | 2.56% | 13.04% | 35.29% | 34.21% | 398.03% | -70.65% | -16.13% | 24% | 38.89% | 63.64% | 81.22% | - |
| EPS (Basic) | - | 0.57 | 0.23 | 0.09 | 0.31 | 0.27 | 0.73 | 0.95 | 0.87 | 0.97 | 0.80 | 0.78 | 0.69 | 0.51 | 0.38 | 0.08 | 0.27 | 0.31 | 0.25 | 0.18 | 0.11 | 0.06 |
| Diluted Shares Outstanding | 680.58M | 680.58M | 680.02M | 679.76M | 679.81M | 681.56M | 685.52M | 663.69M | 684.71M | 684.24M | 684.17M | 685.66M | 685.34M | 681.01M | 685.4M | 659.52M | 441.59M | 483.83M | 486.73M | 489.97M | 429.58M | 421.25M |
| Basic Shares Outstanding | 680.58M | 680.58M | 680.02M | 679.76M | 679.81M | 681.56M | 685.52M | 659.98M | 684.71M | 684.2M | 683.23M | 685.28M | 685.34M | 681.01M | 685.4M | 659.52M | 433.86M | 483.83M | 486.73M | 489.97M | 429.58M | 421.25M |
| Dividend Payout Ratio | - | 31.84% | 0.61% | - | 0.32% | 133.76% | 18.31% | 38.19% | 46.74% | 32.93% | 39.63% | 41.68% | 33.18% | 20.28% | - | - | 23.62% | 54.68% | 28.58% | 14.59% | 15.42% | 11.11% |
High leverage and governance
According to the latest quarterly income statements, Grifols' revenue growth has decelerated into negative territory, with 2026Q1 revenue falling to $1.7 billion, representing a 3.2% year-over-year decline that highlights the difficulty in maintaining top-line momentum amidst a challenging plasma collection and pricing environment.
The transition from mid-single-digit growth in 2025 to contraction in early 2026 suggests that the company is struggling to offset volume pressures with pricing power. Investors should monitor whether this decline reflects a broader saturation in the U.S. plasma market or specific operational bottlenecks in the fractionation process.
As reported in recent financial filings, Grifols' gross margin contracted to 36.5% in 2026Q1, down from the 40% levels observed in mid-2025, indicating that rising input costs and donor compensation are effectively eroding the profitability of the company's core plasma-derived medicinal products.
The inability to sustain gross margins above 40% suggests that the company lacks the pricing elasticity required to fully pass on inflationary pressures to healthcare providers. This margin volatility warrants further investigation into the long-term sustainability of the current cost-per-liter structure.
Based on the provided income statement data, operating income fell to $253.1 million in 2026Q1, reflecting a significant decline from the $383.3 million peak in 2025Q3, which suggests that the company's fixed cost base is not scaling efficiently with current revenue levels.
The erratic nature of operating margins, which fluctuated between 12.5% and 20.5% over the last ten quarters, implies that management has yet to achieve the necessary operational discipline to protect profitability during revenue downturns. This lack of operating leverage may indicate that the company's infrastructure remains oversized relative to its current output.
Analysis of the quarterly income statements reveals that net income remains highly inconsistent, with 2026Q1 net income of $74.2 million appearing significantly detached from the operational volatility observed in the gross profit line, suggesting that non-operating items or tax fluctuations may be distorting the bottom line.
The wide variance in quarterly EPS, ranging from $0.02 to $0.19, indicates that investors should be cautious when relying on headline net income as a proxy for core business health. The absence of stock-based compensation in the reported figures warrants further investigation into how management incentives are aligned with shareholder interests.
While the company reports positive net income, the historical reliance on related-party transactions and complex debt structures, as noted in market intelligence, suggests that the reported earnings quality may be lower than the headline figures imply, creating a persistent complexity discount for investors.
Short-sellers likely focus on the discrepancy between reported EBITDA and actual cash generation, particularly given the historical involvement of related-party vehicles. Until the balance sheet is simplified and transparency regarding minority interests is improved, the market may continue to apply a valuation discount regardless of operational performance.
Quick answers to the most common questions about buying GRFS stock.
For fiscal year 2025, Grifols, S.A. (GRFS) reported total revenue of $7.23B. This represents a 1278.5% increase compared to $524.3M in 2005.
Grifols, S.A. (GRFS) is profitable, generating $386.1M in net income for the fiscal year ending 2025 with a net profit margin of 5.3%.
Grifols, S.A. (GRFS) reported an operating income of $1.19B, resulting in an operating profit margin of 16.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Grifols, S.A. (GRFS) generated $2.58B in gross profit for the year, representing a gross profit margin of 35.7%. This demonstrates the company's core pricing power and production efficiency.